Entero Therapeutics, Inc.
ENTO
$1.94
$0.042.11%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -22.02% | -37.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -22.22% | -31.75% | |||
| Operating Income | 22.22% | 31.75% | |||
| Income Before Tax | 28.82% | 20.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 28.82% | 91.96% | |||
| Earnings from Discontinued Operations | -3.79% | 29.12% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.74% | 89.71% | |||
| EBIT | 22.22% | 31.75% | |||
| EBITDA | 22.32% | 33.94% | |||
| EPS Basic | 19.43% | 91.30% | |||
| Normalized Basic EPS | 19.59% | -136.69% | |||
| EPS Diluted | 31.24% | 89.80% | |||
| Normalized Diluted EPS | 19.59% | -136.69% | |||
| Average Basic Shares Outstanding | 0.00% | 38.72% | |||
| Average Diluted Shares Outstanding | 0.00% | 38.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||